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ABSTRACT 75 
 76 
During Theiler’s virus (TMEV) infection of macrophages it is thought that high IL-6 levels 77 
contribute to demyelinating disease found in chronically infected SJL/J mice but absent 78 
in B10.S mice capable of clearing the infection.  Therefore, IL-6 expression was 79 
measured in TMEV-susceptible SJL/J and TMEV-resistant B10.S macrophages during 80 
their infection with TMEV DA strain or responses to LPS or poly I:C.  Unexpectedly, IL-6 81 
production was greater in B10.S macrophages than SJL/J macrophages during the first 82 
24 h after stimulation with TMEV, LPS or poly I:C.  Further experiments showed that in 83 
B10.S, SJL/J, and RAW264.7 macrophage cells, IL-6 expression was dependent on 84 
extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) 85 
and enhanced by exogenous IL-12.  In SJL/J and RAW264.7 macrophages, exogenous 86 
IL-6 resulted in decreased TMEV replication, earlier activation of STAT1 and STAT3, 87 
production of nitric oxide, and earlier up-regulation of several anti-viral genes 88 
downstream of STAT1.  However, neither inhibition of IL-6-induced nitric oxide nor 89 
knockdown of STAT1 diminished the early anti-viral effect of exogenous IL-6. In 90 
addition, neutralization of endogenous IL-6 from SJL/J macrophages with Fab 91 
antibodies did not exacerbate early TMEV infection. Therefore, endogenous IL-6 92 
expression after TMEV infection is dependent on ERK MAPK, enhanced by IL-12, but 93 
too slow to decrease viral replication during early infection.  In contrast, exogenous IL-6 94 
enhances macrophage control of TMEV infection through preemptive anti-viral nitric 95 
oxide production and anti-viral STAT1 activation.  These results indicate that immediate-96 
early production of IL-6 could protect macrophages from TMEV infection.  97 
 98 
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INTRODUCTION 99 
Interleukin (IL)-6 is a pleiotropic cytokine expressed by many cell types that is induced 100 
by microbes and other cytokines.  IL-6 can play a beneficial role during immune 101 
response by contributing to neutrophil activity, nitric oxide production and development 102 
of the Th17 CD4 T cell subset, and a beneficial role in the brain (43) and neuronal 103 
health (9, 11). In contrast, persistent IL-6 induction during infection can contribute to 104 
detrimental effects on surrounding neurons or bone and poor control of cancer or 105 
autoimmune responses (24). During microbial induction of IL-6, activation of p38 106 
mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase 107 
(ERK) MAPK signaling pathways contribute to IL-6 expression (21, 49) and stabilization 108 
of IL-6 mRNA (2) for protein translation.  109 
Macrophages express IL-6 when they encounter microbes such as bacteria, 110 
fungi, or viruses (44).  While the neutrophil- and Th17-promoting activity of IL-6 is critical 111 
in controlling certain bacterial or fungal infections, less is known about the role of IL-6 in 112 
viral infections. Recently, an antiviral role for IL-6 has been shown in mouse poxvirus 113 
infections, where early IL-6 production is required to control a potentially lethal infection 114 
(30), and in lymphocytic choriomeningitis virus infection, where late IL-6 production was 115 
shown to be critical for clearance of persistent viruses (12). However, failure to clear 116 
viruses from infected macrophages could result in viral spread to other tissues due to 117 
macrophage chemotaxis and could result in persistent IL-6 expression in affected tissue 118 
causing inflammatory pathologies and autoimmune diseases (16).  Similarly, persistent 119 
elevation of IL-6 is associated with the development of experimental autoimmune 120 
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encephalomyelitis (EAE) in mice immunized peripherally with myelin peptides, whereas 121 
mice deficient in IL-6 are resistant to development of EAE (32, 40).  Such data suggests 122 
that IL-6 expression may be essential to control early viral infection, yet contribute to 123 
pathology when expressed persistently. 124 
Theiler’s murine encephalomyelitis virus (TMEV) causes an acute infection that is 125 
cleared through innate and adaptive immune responses in most mouse strains yet 126 
produces debilitating sequelae in susceptible mice (33).  C57Bl/6 and B10.S mice are 127 
prototypical TMEV-resistant strains whereas SJL/J mice fail to clear TMEV from 128 
macrophages and dendritic cells, resulting in persistent infection (25).  Subsequent 129 
infection of macrophages in the central nervous system (CNS) of SJL/J mice leads to a 130 
demyelinating disease similar to human multiple sclerosis(5).  Several reports have 131 
shown that a week after infection with TMEV, CNS macrophages, microglial cells, and 132 
astrocytes from SJL/J mice express IL-6 to a greater extent than C57Bl/6 mice (14, 17, 133 
34).  A proposed theory is that chronic production of IL-6 in the CNS of persistently 134 
infected SJL/J mice contributes to demyelinating disease in response to TMEV(17).   135 
We propose that the dichotomy of TMEV persistence seen in resistant and 136 
susceptible macrophages depends on early differences in the cytokine production.  We 137 
have previously shown that B10.S macrophages produce more IL-12 p70 in response to 138 
TMEV infection than SJL/J macrophages in vitro (37).  Significantly, when SJL/J 139 
macrophages are pretreated with IL-12, TMEV replication is reduced to levels 140 
comparable with B10.S macrophages.  Paradoxically, SJL/J macrophages express 141 
more interferon (IFN)β than B10.S macrophages before and during infection with 142 
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TMEV(37), yet this enhanced endogenous IFNβ expression is insufficient to control 143 
TMEV replication.  However, pretreatment with additional exogenous recombinant IFNβ 144 
decreases TMEV replication in SJL/J macrophages to amounts seen in B10.S 145 
macrophages (37). We found that p38 ERK MAPK pathways are activated in response 146 
to TMEV infection of B10.S or SJL/J macrophages and play a role in IL-12 and IFNβ 147 
expression (37).  Therefore, differences in MAPKs, IL-12, and IFNβ may be related to 148 
disparities in susceptibility of macrophages to persistent infection with TMEV.   149 
In order to further understand the differences between SJL/J and B10.S mice that 150 
could account for differences in TMEV persistence, we examined IL-6 expression in 151 
macrophages during the early response to TMEV.  Unexpectedly, we found that during 152 
early response to infection with TMEV, B10.S macrophages expressed significantly 153 
more IL-6 than SJL/J macrophages.  Moreover, pre-treatment of macrophages with 154 
exogenous IL-6 reduced TMEV replication but neutralization of endogenous TMEV-155 
induced IL-6 with Fab antibodies failed to affect TMEV replication in SJL/J 156 
macrophages.  Additionally, we show that TMEV-induced IL-6 secretion in 157 
macrophages depends on ERK-MAPK and is enhanced by IL-12.  However, neither IL-158 
6-induced nitric oxide production nor STAT1 activation are essential to IL-6 reducing 159 
TMEV infection. 160 
MATERIALS AND METHODS 161 
Mice, virus, cell lines, and reagents.  The eight to twelve week old female B10.S and 162 
SJL/J mice were obtained from Jackson Laboratories (Bar Harbor, Maine).  RAW264.7 163 
cells were obtained from the American Type Culture Collection (Rockville, MD) and 164 
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maintained in DMEM with 10% FBS with 50 μg/ml gentamycin. The p38 MAP-kinase 165 
inhibitor SB203580 and ERK MAPK inhibitor U0126 were obtained from Promega 166 
Corporation (Madison, WI), E. coli LPS O127:B8 was obtained from Sigma Chemical 167 
Co.(St. Louis, MO), and poly I:C was obtained from InvivoGen (San Diego, CA).  The 168 
inducible nitric oxide synthase inhibitor, L-NIL, was obtained from TOCRIS Bioscience 169 
(Bristol, UK) and incubated with macrophages where indicated at 10 μM.   The nitric 170 
oxide donor spermine NONOate was obtained from Invitrogen (Carlsbad, CA) and 171 
incubated with macrophages where indicated at 1 mM. Affinity purified neutralizing rat 172 
antibody to mouse IL-6 (clone MP5-20F3) (48) was obtained from Invitrogen. Fab 173 
fragments of neutralizing anti-IL-6 were obtained after papain digestion using the Fab 174 
preparation kit of Pierce (Thermo Fisher Scientific, Rockford, IL).  The initial stock of the 175 
DA strain of TMEV was obtained from Dr. Kristen Drescher, Department of Medical 176 
Microbiology and Immunology, Creighton University, Omaha, Nebraska.  TMEV was 177 
grown in BHK-21 cells.  The titer of stock cultures of TMEV was 2.5 x 106 PFU/ml and 178 
macrophages cultures were infected with 2.5 x 105 PFU of TMEV unless otherwise 179 
stated.    180 
Macrophage preparations. Macrophages were elicited by intraperitoneal 181 
injection of 2 ml thioglycollate broth into mice.  Four days later, the peritoneal cavities 182 
were each flushed with 2 ml DMEM and the cells were incubated at 1 x 106   cells/2 ml 183 
of DMEM cell culture medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine 184 
serum (FBS) (Invitrogen), and 50 μg/ml gentamycin (Invitrogen).  After 24 h, non-185 
adherent cells were removed and 1 ml of culture medium added.   Adherent cells were 186 
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greater than 90% Mac-1+ as determined by FACS analysis.  These macrophages were 187 
either untreated or pretreated for 30 min with 20 μM of SB203580, 40 μM U0126, 1 188 
ng/ml IL-12 p70 (p35/p40; BD-Pharmingen, San Diego, CA), 10 ng/ml IFNβ 189 
(Minneapolis, MN) or 10 ng/ml IL-12 p40 (BD-Pharmingen).  Untreated or pretreated 190 
macrophages were uninfected, infected with 100 μl of the TMEV stock (2.5 x 105 PFU), 191 
stimulated with 1 μg/ml LPS, or stimulated with 50μg poly I:C or left unstimulated.  After 192 
3, 8, or 24 h of infection or stimulation, supernatants were collected for ELISA and cell 193 
extracts were collected for RNA preparation and quantitative RT-PCR. 194 
RNA interference. Validated inhibitory siRNA targeting mouse STAT1 and 195 
STAT3 was purchased from Cell Signaling, Inc. (Danvers, MA) and transfected into 196 
RAW264.7 cells according to manufacturer’s specifications using the nucleofection kit of 197 
Amaxa 36 h prior to challenge with TMEV.   198 
RNA preparation and quantitative RT-PCR. RNA was extracted from cells 199 
using the RNAeasy kit of Qiagen (Valencia, CA), PerfectPure kit from 5Prime 200 
(Gaithersburg, MD), or the Purelink kit from Ambion/Invitrogen (Carlsbad, CA) according 201 
to the manufacturer’s specifications.  One-hundred ng to one μg of RNA was reverse 202 
transcribed in 0.5 mM each of dATP, dGTP, dTTP, and dCTP, 20 U of RNAse inhibitor 203 
with Superscript II reverse transcriptase (Invitrogen) at 42oC for 1.5 h followed by 94oC 204 
for 5 min.  One twenty-fifth of the cDNA sample was incubated with 0. 4 μM of the 205 
following primer pairs (Invitrogen): IFNβ sense 5’ ATGAACAACAG GTGGATCCTCC 3’ 206 
and anti-sense 5’ AGGAGCTCCTGACATTTCCGAA 3’; IL-6 sense 5′ ATGAAGTTCCT 207 
CTCTGCAAGAGACT 3’ and antisense 5′ CACTAGGTTTGCC GAGTAGATCTC 3′; 208 
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IRF1 sense 5’ ATGCCAATCACTCGAATGCGGA 3’ and antisense 5’ GGCTGC 209 
CACTCAGACTGTTCAA 3’; IRF-7 sense 5′ CCAGCGAGTGC TGTTTGGAGAC 3′ and 210 
antisense 5′ TTCCCTATTTTCCGTGGCTGGG 3′; IRF-9 sense 5’ ATGGCCTCA 211 
GGCAAAGTACGCT 3’ and antisense 5’ TTCGCTTGCATGG TGATTTCTG 3’;  TMEV 212 
sense 5’ CTTCCCATTC TACTGCAATG 3’ and antisense 5’ GTGTTCCTGG 213 
TTTACAGTAG3’; or GAPDH sense 5’-TTGTCAGCAA TGCATCCTGCAC-3’ and 214 
antisense 5’-ACAGCTTTCCA GAGGGGCCATC-3’.  Quantitative PCR reactions were 215 
run on an ABI Prism 7000 thermal cycler at 50 °C for 2 min, 95 °C for 10 min, 45 cycles 216 
of 95 °C for 15 s/60 °C for 30 s. Cycle thresholds (Ct) of sample were normalized to Ct 217 
of GAPDH for that sample (∆Ct), and then normalized to the average ∆Ct of the control 218 
samples (∆∆Ct) after which data are expressed as relative levels of mRNA using 2-∆∆Ct.  219 
When macrophages are pretreated, TMEV RNA data are reported as percentage of 220 
TMEV RNA in non-treated but infected macrophages. 221 
ELISAs.  ELISA plates were coated with antibodies to mouse IL-6 (MP5-222 
20F3;BD-Pharmingen), the plates were blocked with PBS/10% FBS.   After washes, cell 223 
culture supernatants or serial dilutions of recombinant IL-6 (BD-Pharmingen) were 224 
added to wells.   After 2 h, biotinylated antibody to mouse IL-6 (MP5-32C11;BD-225 
Pharmingen) was added to each well. After 1 h, strepavidin horseradish peroxidase 226 
(1:1000; BD-Pharmingen) was added for 30 min and then 3,3', 5, 5' 227 
Tetramethylbenzindine substrate/hydrogen peroxide solution (BD-Pharmingen) was 228 
added to each well.  IL-6 was measured by determining optical densities at OD 450 nm 229 
wavelength with reference OD 570 nm using an ELISA spectrophotometric plate reader. 230 
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PAGE and western blot analysis. Cell lysates were obtained from RAW cells 231 
challenged with TMEV with or without treatment with 10 ng/ml recombinant murine IL-6 232 
(BD-Pharmingen, San Diego, CA) or murine recombinant IFNβ (Interferon Source, 233 
Piscataway, NJ). Twenty μl of each sample containing 20 μg of protein in sample buffer 234 
with bromophenol blue was run on a 10% SDS, Tris-glycine- polyacrylamide gel and 235 
transferred to a nitrocellulose membrane. The membrane was treated with blocking 236 
buffer for 1 h at room temperature, followed by incubation in 1:500 dilution of rabbit IgG 237 
anti-phospho-STAT1(Invitrogen, Camarillo, CA), 1:1000 dilution of anti-phospho-STAT3 238 
(Cell Signalling, Beverly, MA), 1:500 dilution of anti-mouse STAT1(Invitrogen), 1:1000 239 
dilution of anti-mouse STAT3 (Invitrogen), or 1:500 mouse anti-tubulin E7 240 
(Developmental Studies Hybridoma Bank, University of Iowa) and then 1:5000 dilution 241 
of IRDye® 800CWGoat Anti-Rabbit IgG (Rockland Immunochemicals, Inc.,Gilbertsville, 242 
PA) or Alexa Fluor680-labeled anti-Mouse IgG (Rockland Immunochemicals). The 243 
washed membrane was scanned with a LICOR Odyssey® Infrared Imaging System and 244 
densitometric analysis done with LICOR imaging software. 245 
Nitric Oxide Assay. Induction of nitric oxide (NO) was assayed in culture 246 
supernatants by measuring nitrite using the Greiss reagent kit of Invitrogen. Briefly, 20 247 
μL of Griess Reagent was mixed with 150 μL of supernatant plus 130 μL of deionized 248 
water and incubated for 30 min at room temperature. Color development at 570 nm, 249 
which is proportional to nitric oxide in supernatants, was measured with a 250 
spectrophotometer. 251 
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Statistical analysis.  The Student’s t test of the GraphPad Prism Software was 252 
used to determine the significance of differences between means; p < 0.05 was 253 
considered significant. 254 
 255 
RESULTS  256 
TMEV-induced IL- 6 production is greater in TMEV-resistant B10.S macrophages. 257 
IL-6 contributes to both antiviral immunity and virus-induced pathology (3, 41).  TMEV is 258 
cleared from macrophages of TMEV-resistant mice but persists in (CNS) macrophages 259 
in susceptible SJL/J mice (5). Therefore, IL-6 mRNA and protein from TMEV-260 
susceptible SJL/J and TMEV-resistant B10.S macrophages were determined following 261 
challenge with TMEV.  IL-6 mRNA was detected at 3 and 8 h after TMEV challenge 262 
(Fig. 1 A) in both B10.S and SJL/J macrophages, however B10.S macrophages 263 
produced more IL-6 mRNA than SJL/J macrophages at 8 h after infection.  Similarly, 264 
B10.S macrophages produced significantly more IL-6 protein 8 h after TMEV challenge 265 
compared with SJL/J macrophages in response to TMEV (Fig. 1 B). Because TMEV 266 
RNA replication is significantly higher in SJL/J macrophages compared with B10.S 267 
macrophages (37), the data here suggest that enhanced early IL-6 production may 268 
contribute to better control of TMEV replication.  269 
To determine if exogenous IL-6 could impede TMEV replication in SJL/J 270 
macrophages during early infection, recombinant IL-6 was added to SJL/J macrophages 271 
30 min prior to TMEV infection and either left in the media during infection or washed 272 
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out by changing the media just prior to infection.  Treatment with 10 ng/ml exogenous 273 
IL-6 significantly reduced TMEV replication at 8h post infection (PI) in SJL/J 274 
macrophages (Fig. 1C). In addition, treatment with as little as 0.1 ng/ml of exogenous 275 
IL-6 significantly reduced TMEV RNA at 24 h PI in SJL/J macrophages (Fig. 1D).  276 
Equally significant, IL-6 preemptively triggered anti-viral activity in SJL macrophages 277 
even when exogenous IL-6 was added for only 30 min and washed out prior to infection 278 
(Fig. 1D).  These findings suggest that early differences in the amount of IL-6 present 279 
during the course of infection play an important role in the establishment of TMEV in 280 
SJL/J macrophages.   281 
To examine whether TMEV-induced endogenous IL-6 contributes to control of 282 
TMEV replication in SJL/J mice, neutralizing anti-IL-6 (IgG; clone MP5-20F3) antibody 283 
was added to SJL/J macrophages at the time of TMEV infection (48).  Surprisingly, 284 
addition of either whole anti-IL-6 antibody or isotype control antibody both resulted in a 285 
significant reduction in TMEV replication (see Fig. S1A and S1B).  These findings do not 286 
preclude an antiviral role for IL-6, since interactions between the IgG antibody and Fcγ 287 
receptors may also induce anti-viral immunity in macrophages. Indeed addition of 288 
isotype antibody had a similar effect on TMEV infection of macrophages.  Therefore we 289 
treated the whole antibody with papain and removed the Fc fragments to generate Fab 290 
anti-IL-6.  Addition of Fab anti-IL-6 to SJL/J macrophages at the time of infection did not 291 
decrease but also did not increase TMEV replication in infected SJL/J macrophages 292 
(Fig. 1E).     293 
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 To determine the time frame at addition in which exogenous IL-6 is most effective 294 
at reducing TMEV RNA we added 10 ng/ml recombinant IL-6 at 1, 3, 6, and 7 h after or 295 
exogenous IFNβ 7h PI of SJL/J macrophages with TMEV.  Addition of exogenous IL-6 296 
at 1 and 3 h PI significantly reduced TMEV RNA compared with untreated SJL/J 297 
macrophages that were infected with TMEV (Fig. 1F).  Addition of IL-6 at 6 and 7 h PI 298 
failed to significantly reduce TMEV RNA in SJL/J macrophages compared to untreated 299 
macrophages.  In contrast addition of IFNβ at 7 h PI significantly reduced TMEV RNA in 300 
SJL/J macrophages. Thus, while small amounts of added IL-6 were capable of 301 
controlling TMEV replication in SJL/J macrophages in vitro, it appears that a sufficient 302 
quantity of endogenous IL-6 is not produced quickly enough to provide protection 303 
because the beneficial effects of IL-6 are only evident prior to 6 h PI.  These results 304 
confirm that the antiviral effect of IL-6 is most effective very early during the course of 305 
TMEV infection of macrophages.  These findings warrant further investigation into strain 306 
differences in early TMEV-induced IL-6 expression.     307 
TMEV-induced IL-6 expression in macrophages is dependent on ERK 308 
MAPK. The cell signaling pathway activated by TMEV infection leading to IL-6 309 
expression in macrophages is not well understood.  We previously showed that TMEV 310 
infection of macrophages from both B10.S and SJL/J mice strongly activates ERK 311 
MAPK and weakly activates p38 MAPK  (37).  Therefore, macrophages from B10.S and 312 
SJL/J mice were pretreated with ERK and p38 MAPK inhibitors 30 min prior to TMEV 313 
infection.  Twenty-four h after infection, the amount of TMEV-induced IL-6 protein 314 
secreted by B10.S macrophages was significantly greater than that secreted by SJL/J 315 
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macrophages (Fig. 2 B).  In contrast the 24 h TMEV-induced IL-6 mRNA was 316 
significantly higher in SJL/J macrophages than B10.S macrophages, suggesting 317 
translational control of IL-6.  Moreover, TMEV-induced IL-6 mRNA expression was 318 
increased in macrophages treated with the p38 MAPK inhibitor, SB203580, (Fig. 2 A) 319 
but IL-6 protein production was unchanged (Fig. 2 B).   Pretreatment of macrophages 320 
with the ERK MAPK inhibitor, U0126, significantly decreased TMEV induction of IL-6 321 
mRNA (Fig. 2 A) and protein (Fig. 2 B) in both SJL/J and B10.S macrophages 322 
responding to TMEV.  These results indicate that ERK MAPK activation is required for 323 
IL-6 expression in response to TMEV infection and suggest that TMEV-induced IL-6 324 
expression is under translational control.  325 
We have also shown that the TLR3 pathway is involved in macrophage cytokine 326 
responses to TMEV infection by inducing IFNβ, IL-12, and IL-23 (1). Therefore, we 327 
compared the response of macrophages from each strain when treated with the TLR3 328 
agonist, polyI:C or the TLR4 agonist, LPS.   B10.S macrophages expressed significantly 329 
more IL-6 mRNA and protein than SJL/J macrophages treated with LPS (Fig. 3 A, B) or 330 
polyI:C (Fig. 3 C, D), but in macrophages from both strains the level of IL-6 expression 331 
in response to poly I:C was substantially less than that in response to LPS or TMEV.  332 
Because ERK MAPK is activated by both TLR3 agonists (see Fig. S2)  and TLR4 333 
agonists (37), macrophages were also pretreated with U0126.  Inhibition of ERK MAPK 334 
activation with U0126 significantly reduced IL-6 expression to the same extent in both 335 
B10.S and SJL/J macrophages responding to LPS and significantly decreased IL-6 336 
production from SJL/J macrophages responding to polyI:C.  Therefore, ERK MAPK 337 
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activation is required for IL-6 expression that occurs from activation of TLR3 and TLR4 338 
pathways in SJL/J macrophages. 339 
IL-6 expression by macrophages in response to TMEV is enhanced by IL-340 
12. Previously, we showed that SJL/J macrophages responding to TMEV express 341 
significantly more IFNβ and IL-12 p40 (p40/p40) but significantly less IL-12 p70 342 
(p35/p40) than B10.S macrophages.  In addition we showed that addition of IFNβ, IL-12 343 
p40, or p70 decreases TMEV replication in SJL/J macrophages (37).  To see if these 344 
cytokines could affect TMEV-induced IL-6, B10.S and SJL/J macrophages were 345 
pretreated with the IL-12 p40 homodimer, bioactive IL-12 p70, or IFNβ 30 min prior to 346 
and during TMEV challenge. Treatment with IL-12 p70 or p40 significantly enhanced IL-347 
6 expression in response to TMEV in both B10.S and SJL/J macrophages at 24 and/or 348 
48 h post TMEV infection (Fig. 4 A, B), however the modest increase in IL-6 expression 349 
upon pretreatment with IFNβ was not significant (Fig. 4 ).  As we have seen before, IL-350 
12 and IFNβ treatment reduced TMEV replication in both B10.S and SJL/J 351 
macrophages (Fig. 4C).  Therefore deficient production of IL-12 during response to 352 
TMEV could contribute to diminished IL-6 expression by SJL/J macrophages. 353 
To gain further insight into the role of IL-12 in IL-6 expression, we used the 354 
RAW264.7 macrophage cell line which is permissive for TMEV replication, expresses 355 
IL-6 well, expresses IL-12 poorly, and activates ERK MAPK following TMEV infection 356 
(26, 37). To confirm the effects of IL-12 and the ERK MAPK inhibitor on IL-6 expression, 357 
RAW264.7 cells were treated with IL-12 with or without U0126 during TMEV infection.  358 
Pretreatment with IL-12 enhanced IL-6 mRNA (Fig. 5 A) and protein (Fig. 5 B) 359 
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expression following TMEV challenge of RAW264.7 cells, while pretreatment with 360 
U0126 repressed the IL-12 enhancement of IL-6 (Fig. 5 A, B).  Therefore IL-12 is 361 
involved in IL-6 expression during TMEV infection of macrophages in an ERK MAPK 362 
dependent manner.   363 
IL-6 has direct antiviral activity against TMEV replication in RAW264.7 cells. 364 
We next set out to determine if, when, and at what quantity IL-6 represses TMEV 365 
infection in RAW264.7 cells.  First, RAW264.7 cells were treated with 10 ng/ml 366 
exogenous recombinant IL-6 at 30 min prior to and during challenge with TMEV.  Like 367 
SJL/J macrophages, treatment of RAW264.7 cells with IL-6 significantly decreased 368 
TMEV RNA at 24 h PI (Fig. 6 A).  Interestingly, as little as 0.1 ng/ml significantly 369 
reduced TMEV RNA 24 h PI, (Fig. 6B). Furthermore, IL-6 treatment enhanced IL-6 370 
expression (Fig. 6C) at 24 h PI, but IL-6 treatment did not decrease TMEV RNA at 3 371 
and 8 h PI in RAW264.7 cells (Fig. 6D), suggesting the time period in which TMEV 372 
induced events occur in RAW264.7 are slightly different than that seen in SJL/J 373 
macrophages. 374 
IL-6 antiviral activity against TMEV replication is associated with activation 375 
of STAT1 related anti-viral activity.  Like IFNβ, treatment of macrophages with IL-6 376 
leads to activation of STAT3 by phosphorylation at its tyrosine 705 and activation of 377 
STAT1 at its tyrosine 701 (13).  IL-6 activation of STAT1 could contribute to control of 378 
virus replication (28, 46) by inducing expression of IRF1(22), IRF7(23), and IRF9 that 379 
enhance IFNβ expression.  To determine if IL-6 activates STAT1 and induces 380 
expression of IRFs that are downstream of STAT1 during TMEV infection of 381 
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macrophages, RAW264.7 cells were treated with IL-6, IFNβ, or TMEV alone or in 382 
combination and phospho-STAT1, as well as phoshpo-STAT3 were evaluated by 383 
western blot.  TMEV infection alone failed to activate STAT1 by 30 min PI but did so by 384 
6 h PI (Fig. 7A). In contrast, treatment of RAW264.7 cells with either IL-6 or IFNβ 385 
activated STAT1 and STAT3 as early as 30 min after TMEV challenge. To determine if 386 
STAT1 activation is involved in control of TMEV replication, RAW264.7 cells were 387 
transfected with small inhibitory RNA that has been verified to reduce STAT1 (siSTAT1) 388 
or siSTAT3.  Knockdown of STAT1 resulted in significantly increased TMEV RNA while 389 
knockdown of STAT3 failed to affect TMEV RNA replication in RAW264.7 cells (Fig. 390 
7B).  However, pretreatment of STAT1-knocked-down RAW264.7 cells with exogenous 391 
IL-6 resulted in a reduction of TMEV infection back to a level seen in RAW264.7 cells 392 
infected with TMEV.  Moreover, addition of exogenous IL-6 to STAT3-knocked down 393 
and STAT1/STAT3 double-knocked down RAW264.7 cells significantly reduced TMEV 394 
RNA replication compared with untreated RAW264.7 cells infected with TMEV (Fig. 7B).  395 
Therefore, STAT1 activation contributes to control of TMEV replication and the 396 
activation of STAT3 may negatively impact the antiviral effect of STAT1.  Consistent 397 
with STAT1 activation, treatment of RAW264.7 cells with IL-6 resulted in significant 398 
enhancements of TMEV-induced IRF1 (Fig. 7C), IRF7 (Fig. 7D), IRF9 (Fig. 7E), and 399 
IFNβ (Fig. 7F).  These results confirm that IL-6 can directly limit viral replication in 400 
macrophages early after infection with TMEV by initiating a STAT1 anti-viral program. 401 
IL-6 induces nitric oxide in RAW264.7 cells. IL-6 (42) and activated STAT1 402 
(29) also induce expression of nitric oxide synthase and nitric oxide production, which is 403 
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a potent anti-viral factor (41). Therefore, another possibility is that IL-6 controls TMEV 404 
replication in macrophages by inducing nitric oxide.  To explore this possibility, TMEV-405 
challenged RAW264.7 cells were treated with 10 ng/ml IL-6 in the presence or absence 406 
of L-NIL, an inducible nitric oxide synthase inhibitor (27), and production of nitric oxide 407 
was measured.  TMEV infection of RAW264.7 cells did not result in significant nitric 408 
oxide production at 24 h PI (see Fig. S3A).  However, addition of exogenous IL-6 to 409 
TMEV infected RAW264.7 cell resulted in a significant enhancement of nitric oxide 410 
secretion, which was prevented by L-NIL.  IL-6 or NONOate, a nitric oxide donor, 411 
repressed TMEV replication in RAW264.7 cells (see Fig. S3B).  However, L-NIL did not 412 
reverse the IL-6 repression of TMEV replication in RAW264.7 cells.  Thus, while IL-6 413 
induces nitric oxide and nitric oxide is anti-viral, it does not play the decisive role in the 414 
IL-6-induced antiviral effect observed in macrophages in vitro.    415 
 416 
DISCUSSION 417 
The data herein show that IL-6 protects macrophages early after infection with TMEV by 418 
decreasing virus replication in macrophages.  These results are somewhat surprising 419 
because research on chronic TMEV infection has supported the theory that enhanced 420 
IL-6 may play a detrimental role in the immunopathology of TMEV in susceptible mice 421 
(14). Indeed, a recent report has shown that SJL/J mice infected with TMEV exhibit 422 
greater levels of IL-6 in the CNS than TMEV-resistant C57Bl/6 mice starting at day 8 423 
after infection (14).  However, in that report IL-6 was not measured until day-8 after 424 
infection.  We show herein that the antiviral effect of IL-6 takes place within the first 6 h 425 
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after infection.  Therefore the beneficial effect of IL-6 is early after TMEV infection, but 426 
not later.  It is also possible that TMEV-resistant C57Bl/6 mice may have a different 427 
mechanism to control TMEV infection in macrophages compared with TMEV-resistant 428 
B10.S mice.   The results herein indicate that during the first day after infection in vitro, 429 
IL-6 protein production by macrophages from TMEV-resistant B10.S mice is greater 430 
than from macrophages of TMEV-susceptible SJL/J and this difference may play an 431 
important role in determining the severity of the infection. Moreover, significant levels of 432 
IL-6 are not produced until 8 h after TMEV infection and IL-6 is only effective at 433 
controlling TMEV replication during the first 8 h after infection.  Therefore, IL-6 produced 434 
by the TMEV infected macrophages helps to protect uninfected macrophages from 435 
subsequent infection.  Altogether, the present data suggest the CNS demyelination that 436 
SJL/J mice develop several weeks to months after infection with TMEV may be due in 437 
part to an inability of SJL/J macrophages to control viral replication very early after the 438 
initial infection.  Similarly, B10.S mice that do not develop demyelination following 439 
infection with TMEV may stem from better early control of TMEV replication in 440 
macrophages.   Our results indicate that ability to control TMEV replication in 441 
macrophages begins during the first 24h after infection is to a large extent dependent on 442 
macrophage production of IL-6, which then protects uninfected cells from infection.  443 
Thus, IL-6 production by virally infected cells may have dual roles in viral infection by 444 
contributing to both anti-viral immunity and subsequent pathology.   445 
Several reports have proposed beneficial effects of exogenous IL-6 treatment in 446 
TMEV infection of SJL/J mice (35, 39). In fact, recombinant exogenous IL-6 was shown 447 
to suppress chronic demyelination and reduce virus replication in SJL/J mice infected 448 
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with TMEV. Other reports have shown that IL-6 is involved in neuronal health facilitating 449 
neuronal differentiation, neurite outgrowth, survival, regeneration (47) and 450 
oligodendrocyte differentiation (52). In stark contrast to these reports are others which 451 
have suggested that chronic expression of IL-6 in TMEV-susceptible SJL/J mice is 452 
responsible for development of demyelinating disease (17). Hou et al. (14) showed that 453 
IL-6 levels in the brain and spinal cord of SJL/J mice are elevated 8-90 days post 454 
infection compared with TMEV resistant C57Bl/6 mice. It is possible that the lower early 455 
acute IL-6 response of SJL/J mice to TMEV infection is inadequate to control viral 456 
replication, thereby rendering these mice susceptible to chronic viral infection and a 457 
chronically elevated IL-6 response.   Alternatively, enhanced IL-6 in the CNS of TMEV 458 
infected SJL/J mice may not be a reflection of a heightened IL-6 response of infected 459 
cells to TMEV but may be due to enhanced infiltration of macrophages into the CNS, 460 
which then are infected with TMEV and produce IL-6.   461 
The anti-viral and pathological effects of IL-6 notwithstanding, the signaling 462 
pathways that lead to IL-6 expression in response to TMEV remain unclear.  Previous 463 
reports showed that ERK and p38 MAPK pathways are involved in both innate anti-viral 464 
immunity (7) and IL-6 expression (49).  The results herein confirm that activation of ERK 465 
MAPKs contributes to IL-6 expression in response to TMEV.  However, maximum ERK 466 
activation occurs within 30 min after TMEV infection of macrophages and we have not 467 
noticed differences in the intensity of ERK activation between SJL and B10.S 468 
macrophages following TMEV infection (37, 38).  Activated ERK MAPKs have been 469 
shown to phosphorylate downstream transcription factors such as the cyclic AMP 470 
response element binding protein (CREB) at serine 133 (4, 51, 45), CREB response 471 
21 
 
elements (CRE) are located at the IL-6 promoter (8), activated CREB binds to IL-6 472 
promoter CRE (10), and CREB activity is required for IL-6 (36). Therefore, TMEV 473 
induction of IL-6 is likely to depend on the ERK activation of the transcription factor, 474 
CREB. 475 
The results herein also suggest that TMEV induction of IL-6 in macrophages is in 476 
part dependent upon macrophage production of IL-12, which is also the primary inducer 477 
of Th1 development during adaptive immune responses (15). In addition, our results 478 
show that IL-12 enhancement of IL-6 expression is dependent on the ERK-MAPK 479 
pathway.   Other reports have shown in IL-12 p35 knockout mice that IL-12 plays a 480 
significant role in IL-6 expression during viral infection (18), IL-6 expression depends in 481 
part on activation of ERK (19), and that IL-12 activates ERK-MAPK (20). These results 482 
are consistent with our previous data that showed significantly more IL-12 production 483 
from B10.S macrophages compared with SJL/J macrophages following TMEV infection 484 
(37).  Therefore, IL-12 expression by macrophages that is responsible for Th1 485 
development during adaptive immune responses also contributes to IL-6 expression 486 
during innate immune responses, both roles of IL-12 are likely to be beneficial to early 487 
anti-viral immunity. 488 
Overall the data here suggest a direct, interferon-like role for IL-6 in the 489 
suppression of TMEV replication, which is exemplified by its ability to activate STAT1 490 
and induce expression of STAT1 dependent genes.  Indeed early reports regarding IL-491 
6, which was originally called Interferon-beta 2, showed it to have anti-viral activity (44).  492 
While it is not clear how IL-6 decreases TMEV replication, it is known to be a potent 493 
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inducer of iNOS and nitric oxide production (31), which has anti-viral properties (41). 494 
Our data confirm that IL-6 induces significant nitric oxide production from macrophages 495 
and that nitric oxide does indeed control TMEV replication.  However, preventing IL-6-496 
induced nitric oxide production did not reverse the anti-viral effect of IL-6.  This is most 497 
likely because IL-6 also activated STAT1 and STAT3 that lead to the induction of 498 
STAT1-downstream anti-viral genes, IRF1, IRF7, and IRF9.  Therefore the data suggest 499 
that early after infection with TMEV, IL-6 controls acute viral infection by inducing 500 
multiple innate antiviral programs. 501 
One of the discrepancies noted herein is that between IL-6 mRNA expression 502 
and IL-6 protein secretion at time points beyond 8 h post infection.  These data suggest 503 
that TMEV induced IL-6 production is under translational or inhibitory RNA control, 504 
which is especially notable in the TMEV-susceptible SJL/J macrophages. At 24 and 28 505 
h post infection SJL/J macrophages expressed more IL-6 mRNA but produced less IL-6 506 
compared with B10.S macrophages.  In one study K homology (KH)-type splicing 507 
regulatory protein (KHSRP) was shown to target the AU-rich elements in the IL-6 mRNA 508 
3’ untranslated region which restricts its translation but does not lead to degradation of 509 
mRNA (6). In another study microRNA-365 was shown to inhibit the translation of IL-6 510 
mRNA without affecting IL-6 mRNA (50).  Our results suggest that differences in 511 
translational or inhibitory control of IL-6 expression following infection of macrophages 512 
could contribute to susceptibility versus resistance of macrophages to TMEV. 513 
In summary, our findings show that strain differences in onset and amount of IL-6 514 
upregulation upon infection with TMEV correlate with previously observed differences in 515 
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disease outcomes between B10.S and SJL/J mice.  Whereas B10.S mice with 516 
enhanced early IL-6 are capable of clearing TMEV, in SJL/J mice TMEV replication is 517 
not reduced by IL-6 unless exogenous IL-6 is added, suggesting that these mice do not 518 
produce IL-6 quickly enough or in sufficient quantity to control viral replication.   The 519 
present investigation suggests that enhanced early expression of IL-6 by macrophages 520 
during infection with a macrophage-trophic virus, TMEV, is responsible for better control 521 
of viral replication in TMEV-resistant B10.S macrophages compared with TMEV-522 
susceptible SJL/J macrophages. These results indicate that the persistent TMEV 523 
infection of macrophages in the CNS of SJL/J mice could be the result of insufficient IL-524 
6 production that controls early TMEV infection through multiple anti-viral mechanisms 525 
that include nitric oxide production and STAT1 activation.  Furthermore, the present 526 
data clearly shows that IL-12 and ERK MAPK play a major role in TMEV-induced IL-6.  527 
While ERK MAPK is required for IL-6 expression in response to TMEV its activation is 528 
equivalent in both strains.  In contrast our previous studies point to differences in TLR 529 
signaling and IL-12 expression that may contribute to strain differences in TMEV-530 
induced IL-6.  These results are supported by our data showing that TMEV-induced IL-6 531 
is also antiviral in RAW264.7 cells, IL-6 expression is enhanced by IL-12, and IL-6 leads 532 
to activation of STAT1, expression of its downstream genes IRF1, IRF7, IRF 9, and IFN-533 
beta, as well as induction of nitric oxide.  These results are significant because 534 
persistent infection of SJL/J macrophages by TMEV contributes to the inflammatory 535 
autoimmune demyelination in the CNS of TMEV infected SJL/J mice, which mimics 536 
human Multiple Sclerosis, that is not seen in TMEV infected B10.S mice.    It remains to 537 
be determined if IL-6 is effective at controlling TMEV replication during established 538 
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persistent TMEV infection of macrophage populations.  Nevertheless, this study 539 
suggests therapeutic strategies that promote early IL-6 antiviral pathways could prevent 540 
chronic viral infections. 541 
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FIG 1  TMEV induces more IL-6 expression in macrophages. IL-6 mRNA or protein 739 
secretion was induced from SJL/J or B10.S macrophages 3 and 8 h after infection with 740 
TMEV.  SJL/J or B10.S macrophages (1 x 106) were infected with 2-10 x 105 PFU of 741 
TMEV in the absence (A, B), or presence of 10 ng/ml recombinant (rec) IL-6 (C, E), 742 
0.01–10 ng/ml rec IL-6 (D), 3 μg/ml anti-IL-6-Fab (E), or SJL/J macrophages were 743 
treated with 10 ng/ml rec IL-6 which was removed after 30 min (D), or SJLJ 744 
macrophages were treated with 10 ng/ml rec IL-6 or rec IFNβ starting at 1, 3, 6, or 7 h 745 
PI (F). RNA was reverse transcribed and relative levels of IL-6 mRNA (A) was evaluated 746 
by real-time PCR, IL-6 protein by ELISA (B), and TMEV by real-time PCR (C, D, E,F).   747 
Data are means of 3-5 samples per time point evaluated by the Student t test; * 748 
indicates p<  0.05, ** p< 0.01. 749 
 750 
FIG 2  ERK MAPK activation is required for optimum TMEV-induced IL-6 expression.  1 751 
x 106 macrophages were untreated (nil or control) or pretreated with 20 μM SB203580 752 
(SB) or 40 μM U0126 (U) for 30 min before infection with 2 x 105 PFU of TMEV. After 24 753 
h, relative levels of IL-6 mRNA was evaluated by real-time PCR (A), IL-6 protein 754 
secretion evaluated by ELISA (B), and TMEV RNA by real-time PCR (C). Data are 755 
means of 5 samples from two experiments evaluated by the Student t test.  * with 756 
brackets indicates p <  0.05. 757 
 758 
 759 
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FIG 3  Optimum IL-6 expression in B10.S compared with SJL/J macrophages following 760 
TLR4 and TLR3 stimulation depends on ERK MAPK activation.  1 x 106 macrophages 761 
were untreated (control) or pretreated with U0126 (U) for 30 min before stimulation with 762 
1 μg/ml LPS (A, B) or 50 μg/ml polyI:C (C, D). After 24 h (A, C), relative levels of IL-6 763 
mRNA was evaluated by real-time PCR and (B, D) IL-6 protein secretion evaluated by 764 
ELISA. Data are means of 5 samples evaluated by the Student t test.  * indicates 765 
comparisons considered significantly different; p <  0.05. 766 
 767 
FIG 4  IL-12 and IFNβ enhance IL-6 expression and decrease TMEV replication during 768 
TMEV infection of B10.S and SJL/J macrophages.  1 x 106macrophages from SJL/J and 769 
B10.S mice were untreated (control) or treated with IL-12 p70 (1 ng/ml), IFNβ (10 770 
ng/ml), or IL-12 p40 (10 ng/ml) 45 min before and during infection with 2 x 105 PFU of 771 
TMEV. After 24 and 48 h of infection relative levels of IL-6 mRNA was evaluated by 772 
real-time PCR (A), IL-6 protein was evaluated by ELISA (B), and TMEV RNA was 773 
evaluated by real-time PCR (C). Data are means of 3 samples each evaluated by the 774 
Student t test.  * indicates comparisons considered significantly different; p <  0.05. 775 
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FIG 5  IL-12 and ERK-MAPK contribute to IL-6 expression during TMEV infection of 780 
RAW264.7 macrophages.  1 x 106RAW264.7 macrophage cells were untreated (control) 781 
or treated with IL-12 p70 (1 ng/ml) with or without 40 μM U0126 ERK MAPK inhibitor 45 782 
min before and during infection with 1 x 106 PFU of TMEV. After 24 h of infection 783 
relative levels of IL-6 mRNA (A) was evaluated by real-time PCR and (B) IL-6 protein 784 
was evaluated by ELISA. Data are means of 3 samples each evaluated by the Student t 785 
test. This experiment was repeated three times. * indicates p<  0.05, ** p< 0.01, n.d.= 786 
not detectable. 787 
 788 
FIG 6  IL-6 constrains TMEV replication during infection of RAW264.7 macrophages.  1 789 
x 106RAW264.7 macrophage cells were untreated (control) or treated with 10ng/ml IL-6  790 
(A, C) or 0.01- 10 ng/ml IL-6 (B) during infection with 1 x 106 PFU of TMEV. After 3, 6 791 
(D), or 24 h (A, B, C) of infection relative levels of TMEV (A, B, D) or IL-6 (C) mRNA 792 
were evaluated by real-time PCR.  Means are of 6 samples from two experiments each 793 
evaluated by the Student t test.  * indicates p<  0.05, ** p< 0.01.  794 
 795 
FIG 7  IL-6 activates STAT1 and STAT3 in macrophages.  (A) Western blots of 796 
phospho-STAT1, phospho-STAT3, total STAT3, and beta-tubulin at 30 min and 6 h in 797 
untreated or RAW264.7 cells treated with IL-6 or IFNβ with or without TMEV infection.  798 
(B) TMEV RNA measured by qRT-PCR in RAW264.7 cells transfected with siSTAT1-799 
RNA (3 pmol) or siSTAT3-RNA (3 pmol) and then infected with TMEV at 1 MOI after 36 800 
36 
 
h.   Real-time PCR of IRF1 (B), IRF7 (C), IRF9 (D), and IFNβ (E) in RAW cells treated 801 
with 10 ng/ml IL-6 prior to and during TMEV infection after 3 and 6 h infection.  Data are 802 
means of 5 samples each evaluated by the Student t test.  * indicates means 803 
considered significantly different; p <  0.05; n.d.= not detectable. 804 
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Figure 7. Moore et al. 832 
 833 
 834 
 835 
 836 
    837 
A 
C 
E 
B 
Control   IL-6     TMEV   TMEV    IFNβ       IL-6    TMEV     TMEV 
                           +IL-6               +IL-6 
pSTAT1 Y701 
β-tubulin 
STAT3 
pSTAT3 Y705 
30 minutes 6 hours 
D 
F 
